PhoenixBio Co Ltd

PhoenixBio maintains a strong liquidity position with cash and equivalents amounting to ¥1.385 billion, which is significantly higher than its total liabilities of ¥917.713 million, resulting in a current ratio of 5.06. The company's debt-to-equity ratio of 0.4 indicates a conservative capital structure, with long-term debt of ¥723.931 million compared to total equity of ¥1.798 billion. Despite a revenue of ¥386.69 million, PhoenixBio reported an operating loss of ¥21.109 million, translating to a negative operating margin. The net income of ¥11.995 million suggests that non-operating gains or lower tax expenses offset the operating loss. The return on equity of 0.67% and return on assets of 0.44% indicate that the company is not generating strong returns relative to its equity and asset base. The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess geographic or segment concentration. However, the lack of disclosed segments implies a relatively undiversified business model, which could pose risks if demand in a particular area declines. Looking ahead, PhoenixBio's revenue is expected to grow, though the exact figures are not provided. The company's operating cash flow was negative at ¥85.414 million, and capital expenditures amounted to ¥38.773 million, indicating ongoing investment in infrastructure or expansion. The negative operating cash flow may be a concern if it persists, as it could affect the company's ability to fund operations without external financing. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and low debt levels suggest that it is not under immediate pressure to raise additional capital. However, the negative operating cash flow and operating loss could be potential red flags if they continue into future periods. Recent financial filings and transcripts do not highlight any major events or strategic shifts for PhoenixBio. The company's last actual EPS was -110.18 JPY, and its last actual revenue was ¥1.541 billion, according to analyst estimates. These figures suggest that the company is still in a growth or development phase, with earnings yet to become consistently positive.